Discovery of monocarbonyl curcumin hybrids as a novel class of human DNA ligase I inhibitors: in silico design, synthesis and biology12. Issue 31 (9th March 2016)

• Record Type: Journal Article
• Authors: Mandalapu, Dhanaraju; Singh, Deependra Kumar; Gupta, Sonal; Balaramnavar, Vishal M.; Shafiq, Mohammad; Banerjee, Dibyendu; Sharma, Vishnu Lal
• Is Part Of: RSC advances. Volume 6:Issue 31(2016)
• Page Start: 26003
• Page End: 26018
• Publication Date: 2016-03-09
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c5ra25853g
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : A pharmacophore model identified a novel class of hLigI inhibitors to treat cancer. 36 compounds were synthesized and the identified inhibitor, compound23 shown antiligase activity at IC50 24.9 μM by abolishing the interaction between hLigI and DNA. Abstract : A pharmacophore model was generated and validated by using known human DNA ligase inhibitors for the identification of a novel series of monocarbonyl curcumin–thiourea/thiazole hybrids as human DNA ligase I (hLigI) inhibitors. These compounds (14–49 ) were synthesized and their antiligase and cytotoxic activities were evaluated in vitro . Several compounds from this series have shown significant inhibition of purified hLigI activity and exhibited a low micro molar range of cytotoxic activity against one or more cancer cell lines, with IC50 values ranging from 1.3–48.8 μM. Among these, compound23 showed antiligase activity at an IC50 value 24.9 ± 1.8 μM, and selective cytotoxicity against DLD1 cancer cell line (IC50 value 8.7 ± 1.9 μM) compared to the reference curcumin (IC50 values were 51.9 ± 8.7 μM and 33.2 ± 1.8 μM for antiligase and cytotoxic activities against DLD1 cell line, respectively), and docking studies showed considerable interactions of compound23 with hLigI. This new class of potent hLigI inhibitors will serve as a potential lead for further optimization and drug development.